NovaBridge Biosciences (NBP) EBIT Margin (2023)

NovaBridge Biosciences (NBP) reported EBIT Margin of 789260.0% for Q4 2023, down 23279.43% quarter-over-quarter from 3375.87% in Q3 2023.

NovaBridge Biosciences (NBP) EBIT Margin (2023) Analysis & Trends

NovaBridge Biosciences (NBP) has 1 years of EBIT Margin data on file, last reported at 789260.0% in Q4 2023.

EBIT Margin for Q4 2023 came in at 789260.0%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was 5741.0% (changed N/A YoY), and the FY2023 annual result was 5794.15%, down 237197.0% from the prior year.
EBIT Margin slipped to 789260.0% in Q4 2023 per NBP's latest filing, from 3375.87% in the prior quarter.
Over five years, EBIT Margin peaked at 3375.87% in Q3 2023 and troughed at 789260.0% in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Alterity Therapeutics	767,934.24 Bn	767,934.20 Bn	-	-
2	Belite Bio	55,234.00 Bn	55,234.00 Bn	-	-
3	Quantum Biopharma	17,823.14 Bn	17,823.14 Bn	-	-
4	Legend Biotech	3,624.50 Bn	3,624.21 Bn	242.10 Mn	-6.43%
5	Akari Therapeutics	1,745.73 Bn	1,745.73 Bn	-	-
6	Evaxion A	1,540.85 Bn	1,540.84 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	112.57 Bn	105.33 Bn	2.59 Bn	38.10%
9	Abivax	93.46 Bn	93.46 Bn	-	-
10	NovaBridge Biosciences	331.49 Mn	120.65 Mn	-	-

Download Data